Cybin Inc.(AMEX:CYBN) has launched its Phase 3 pivotal program called PARADIGM, which is aimed at testing the efficacy of its lead candidate, CYB003, for treating Major Depressive Disorder (MDD) in a move that comes after three years of development.
"Just three years after filing an Investigational New Drug application for CYB003, the initiation of our Phase 3 program is a truly significant and gratifying milestone," saidDoug Drysdale, CEO of Cybin.
The design of the PARADIGM program, according to Drysdale, has been shaped by a collaborative process with theFood and Drug Administration (FDA), taking into account the challenges faced by other...
Login or create a forever free account to read this news
Sign up/Log in
